首页> 外文期刊>Investigative radiology >Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
【24h】

Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.

机译:增强脑部疾病:多少造影剂就足够了?将0.2 T下的0.1、0.2和0.3 mmol / kg加德立醇与1.5 T下的0.1 mmol / kg加德立醇进行比较。

获取原文
获取原文并翻译 | 示例
       

摘要

RATIONALE AND OBJECTIVES: To determine the clinical dose of gadoteridol (ProHance, Bracco-Byk Gulden) to use for the assessment of blood-brain barrier breakdown on low-field magnetic resonance (MR) scanners that corresponds to a standard dose of gadoteridol on high-field MR scanners. METHODS: This prospective study was carried out at four centers. A total of 138 patients with suspected or known brain diseases underwent a routine head scan comprising precontrast T2-weighted turbo spin-echo and T1-weighted spin-echo sequences on a 1.5-T MR scanner. After administration of a standard dose of 0.1 mmol/kg gadoteridol, the T1-weighted scan was repeated after a delay of 15 to 20 minutes. For continuing the examination on a 0.2-T MR scanner (Magnetom OPEN, Siemens), a standard-dose T1 spin-echo sequence was started within 30 to 50 minutes of the first injection. Then two additional T1-weighted low-field sequences were each started 5 minutes after two additional doses of 0.1 mmol/kg gadoteridol. Eighty patients with enhancing lesions underwent an intraindividual comparison. Evaluation of the overall numbers of lesions detected and of lesion size and character was performed on-site as well as off-site by two independent readers. RESULTS: The single-dose, low-field sequence detected significantly fewer enhancing lesions (80/95 lesions; P < 0.05), particularly metastases and infarctions, than did the standard-dose, high-field sequence. No statistically relevant differences (reader 1: P = 1; reader 2: P = 0.8) were found between the double- and triple-dose, low-field sequences and the standard-dose, high-field sequence. Primary brain tumors were detected by all postcontrast sequences irrespective of the dose. CONCLUSIONS: At low field, the clinically equivalent dose to 0.1 mmol/kg gadoteridol at high field is 0.2 mmol/kg. A dose of 0.1 mmol/kg gadoteridol is less effective and cannot be recommended for use on extremely low-field scanners.
机译:理由和目的:确定加德替洛的临床剂量(ProHance,Bracco-Byk Gulden),用于评估低场磁共振(MR)扫描仪上血脑屏障的破坏,该剂量对应于高剂量加德替洛的标准剂量场MR扫描仪。方法:这项前瞻性研究在四个中心进行。总共138名可疑或已知脑疾病患者接受了常规的头部扫描,包括在1.5-T MR扫描仪上对比T2加权的涡轮旋转回波和T1加权的旋转回波序列。服用标准剂量的0.1 mmol / kg gadoteridol后,延迟15至20分钟后,重复进行T1加权扫描。为了在0.2-T MR扫描仪(Magnetom OPEN,西门子)上继续检查,在第一次注射后30至50分钟内开始了标准剂量的T1自旋回波序列。然后在两次额外剂量的0.1 mmol / kg gadoteridol后5分钟,分别开始另外两个T1加权的低场序列。对80例病灶增强的患者进行了个人比较。由两个独立的读者在现场和异地对检测到的病变总数,病变大小和特征进行评估。结果:与标准剂量高视野序列相比,单剂量低视野序列检测到的增强病变(80/95病变; P <0.05),尤其是转移灶和梗塞明显更少。在双剂量和三剂量低场序列与标准剂量高场序列之间未发现统计学上的相关差异(阅读器1:P = 1;阅读器2:P = 0.8)。所有造影剂后序列均检测到原发性脑肿瘤,与剂量无关。结论:在低视场下,高视场下0.1 mg / kg gadoteridol的临床等效剂量为0.2 mmol / kg。 0.1 mmol / kg gadoteridol的剂量效果较差,因此不建议在极低场扫描仪上使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号